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a  b  s  t  r  a  c  t
Novel  and  sensitive  plate-based  fluorogenic  anti-factor  Xa (FXa)  assays  were  investigated  to quan-
tify unfractionated  heparin  (UFH)  in  human  plasma  and  whole  blood  within  the therapeutic  ranges  of
0–1.6  U/mL  and  0–0.8  U/mL,  respectively.  Two  fluorogenic  anti-FXa  assay  methods  were  defined  for  low
(0–0.6  U/mL)  and  high  (0.6–1.2  U/mL)  pharmacologically  relevant  UFH  concentration  ranges  in  pooled
human  plasma.  In both  cases  significant  differences  were  observed  at intervals  of 0.2  U/mL  (P  < 0.05).  The
semi-logarithmic  plots  of  the  calibration  curves  in  the  low  and  high  UFH  range were  both  fitted  to  linear
regressions  with  correlation  coefficients  of  0.96  and  >0.99,  respectively.  The  assay  was  also  optimized  for
whole  blood  which  was  capable  of  differentiating  UFH  concentrations  at intervals  of 0.2 U/mL  (P <  0.05)
in the  range  of 0–0.4  U/mL.  The  statistically  different  results  were  fitted  to a  linear  regression  with  a
correlation  coefficient  of  >0.99.  The  results  obtained  in  this  study  could  assist diagnostic  laboratories
towards  improved  monitoring  of UFH  therapy.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
The anticoagulant drugs market is believed to increase to over
D 9 billion in 2014 from D 6 billion in 2008 [1].  Unfractionated
heparin (UFH) has been the parenteral anticoagulant of choice for
more than 50 years [2–4]. Even though new anticoagulant drugs
inhibiting thrombin (30%) and factor Xa (FXa) (70%) are under
clinical development [5–7], UFH continues to be administered for
short-term prophylaxis because it is effective, inexpensive, and a
protamine sulfate antidote exists to rapidly reverse bleeding [8].
Common laboratory monitoring of UFH is carried out by tra-
ditional coagulation tests, such as the clot-based activated partial
Abbreviations: UFH, unfractionated heparin; FXa, factor Xa; APTT, activated
partial thromboplastin time; ACT, activated clotting time; AMC, 7-amino-4-
methylcoumarin; SN-7, Mes-D-LGR-ANSN (C2H5)2 fluorogenic substrate; ANSN,
6-amino-1-naphthalene-sulfonamide; DCU, Dublin City University; ANOVA, anal-
ysis of variance; afu, arbitrary fluorescence units; TEG, thromboelastography; TAS
HMT, thrombolytic assessment system heparin management test; TG, thrombin
generation.
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thromboplastin time (APTT) [9],  chromogenic anti-FXa assays [10],
and the activated clotting time (ACT). Due to some limitations
and drawbacks associated with APTT and ACT, it has been recom-
mended to calibrate the therapeutic APTT range in seconds to the
reference anti-FXa range of 0.3–0.7 anti-FXa U/mL  [11].
Fluorescent detection has been investigated over the last few
years as an alternative technique to clotting and chromogenic
assays. The high sensitivity that this optical measurement can offer
[12] along with its ability to be adapted to a broad range of sample
matrices, makes it an interesting technique to investigate. Many
fluorophores and labelling chemistries are available for different
coagulation proteases such as factor VIIa [13] and factor VIIa-tissue
factor complex [14], thrombin [15], factor VIII [16], factor IX a
[13,17], factor Xa [13,15], factor XIa [18], factor XIIa [19] and fac-
tor XIII [20]. In particular, fluorogenic substrates have been used
to measure thrombin generation over the last ten years to inves-
tigate the effects of UFH in platelet-poor-plasma (PPP) [21] and
platelet-rich-plasma (PRP) [22].
To the best of our knowledge, few publications to date have
evaluated the use of fluorogenic substrates in the development
of anti-FXa assays for monitoring anticoagulant therapy in human
plasma [23,24] with none reported for use in whole blood. A novel
and sensitive plate-based fluorogenic anti-FXa assay in human
plasma was recently investigated to monitor UFH therapy using
one of two commercially available peptide substrates for FXa based
on a 7-amino-4-methylcoumarin (AMC) fluorescent reporter group
0731-7085/$ – see front matter ©  2011 Elsevier B.V. All rights reserved.
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[23]. In this study, it was sought to develop novel fluorogenic
anti-FXa assays to monitor therapeutic UFH concentrations in both
human pooled plasma and whole blood using the only other com-
mercially available FXa fluorogenic substrate.
2. Materials and methods
2.1. Reagents
Water (molecular biology reagent), HEPES (minimum 99.5%
titration), sodium citrate tribasic dihydrate (ACS reagent, ≥99.0%)
and citric acid monohydrate (ACS reagent, 99.0–102.0%) were pur-
chased from Sigma–Aldrich (Dublin, Ireland). Filtered HEPES (pH
7.4; 10 mM)  was prepared and both sodium citrate and citric
acid were made up to 0.1 M.  Citrate–citric acid buffer solution
was prepared at 3.8% sodium citrate and adjusted to ca. pH
5.5 with 0.1 M citric acid. A 100 mM filtered stock solution of
CaCl2 from Fluka BioChemika (Buchs, Switzerland) was  prepared
from a 1 M CaCl2 solution. The fluorogenic substrate Mes-D-LGR-
ANSN (C2H5)2 (SN-7), containing the fluorescent reporter group
6-amino-1-naphthalene-sulfonamide (ANSN), was  acquired from
Haematologic Technologies Inc. (Vermont, USA). Stock solutions of
10 mM in DMSO were stored at −20 ◦C and also protected from light
with aluminum foil. Dilutions of stock solutions were performed
with 10 mM HEPES. The kinetic constants of SN-7 fluorogenic sub-
strate, which refer to the cleavage by the endopeptidase FXa, were
provided by the supplier as follows: Km = 125 M; kcat = 36 s−1;
kcat/Km = 290,000 M−1 s−1. Purified human FXa (serine endopepti-
dase; code number: EC 3.4.21.6) was obtained from Hyphen BioMed
(Neuville-Sur-Oise, France). UFH obtained from bovine lung tissue
was acquired from Sigma–Aldrich (St. Louis, MO). Human pooled
plasma was purchased from Helena Biosciences Europe (Tyne and
Wear, UK). Lyophilized plasma was reconstituted in 1 mL  of water
and left to stabilize for at least 20 min  at room temperature prior
to use.
2.2. Blood sampling
Human blood was locally obtained from one smoking and five
non-smoking healthy volunteers (30–40 years of age; 3 males and 3
females), who had not ingested any pharmacologically active sub-
stances prior to the experiment. Informed consent was granted
by all volunteers and the study was approved by the Dublin City
University (DCU) ethics committee. Samples were drawn through
antecubital venipuncture at the School of Health and Human Per-
formance in DCU. 10 mL  of venous blood was collected into plastic
20 mL  sterile BD Luer-LokTM syringes from Becton, Dickinson and
Company (Drogheda, Ireland), containing 3.8% sodium citrate at a
ratio of 1:10 in blood using sterile VenisystemsTM Butterfly®-19
needles from Abbott (Sligo, Ireland).
2.3. Apparatus
Absorbance and fluorescence intensities were measured on
an Infinite M200 microplate reader from Tecan Group Ltd.
(Männedorf, Switzerland) equipped with a UV Xenon flashlamp.
Flat, black-bottom 96-well polystyrol FluorNuncTM microplates
from Thermo Fisher Scientific (Roskilde, Denmark) were used for
fluorescence measurements, and flat, transparent 96-well Greiner®
microplates from Greiner Bio-One (Gloucestershire, United King-
dom) for absorbance readings.
2.4. Absorbance and emission spectra of whole blood samples
The total volume of samples in the absorbance and emission
fluorescence experiments was 150 L, which corresponds to the
same final volume as used in the fluorogenic anti-FXa assay. Human
blood samples were diluted 1:150 in water and their absorption
spectra were measured at 2 nm intervals with the Infinite M200
microplate reader from 280 to 1000 nm.  Background fluorescence
emission spectra were evaluated at the excitation wavelength of
352 nm,  which corresponds to that of the ANSN-based fluorogenic
substrate, starting at 400 nm up to 850 nm at 2 nm reading intervals.
Whole blood was  diluted 1:3 in water. All samples were scanned
at 37 ◦C and after the assay was  run.
2.5. Optimization of fluorogenic anti-FXa assays
Measurements were carried out in reconstituted citrated human
pooled plasma and citrated human whole blood. All assays using
human whole blood were initiated within 15 min of collecting
the blood samples. The same experimental protocol was used for
both matrices, the only difference being the titration range of both
FXa and SN-7 fluorogenic substrate. In the presence of citrated
human pooled plasma, FXa and the ANSN-based fluorogenic sub-
strate were titrated within the ranges of 0.1–200 nM and 8.3–75 M
(Km = 125 M),  respectively. In the case of citrated human whole
blood, FXa and the fluorogenic substrate were titrated from 300
to 500 nM and from 75 to 125 M,  respectively. The experimental
protocol was as follows: samples consisting of 6.25 L of 100 mM
CaCl2, 43.75 L of pooled plasma or citrated whole blood, and 50 L
of FXa (within the titration ranges) were incubated at 37 ◦C for 3 min
and shaken for the first 150 s. The reaction was started by adding
50 L of ANSN-based fluorogenic substrate within the titration
ranges as previously described. Samples within wells were mixed
with the aid of orbital shaking at 37 ◦C for 30 s. Finally, immediately
after shaking, fluorescence measurements were recorded at 37 ◦C
for 60 min  with 20 s integration time. Fluorescence excitation was
at 352 nm and emission was monitored at 470 nm,  corresponding
to the excitation/emission wavelengths of the ANSN fluorophore.
All measurements were carried out in triplicate. Following opti-
mization of assay conditions, pooled commercial plasma and whole
blood samples were spiked with therapeutically relevant con-
centrations of UFH from 0 to 1.6 U/mL and from 0 to 0.8 U/mL,
respectively. The reaction rate (slope), which is defined as the
change in fluorescence divided by the change in time (i.e. dF/dt),
was measured as the linear portion of the fluorescence response
profile and plotted versus anticoagulant concentration.
2.6. Software and statistical analysis
All graphs were plotted using SigmaPlot 8.0. Statistical analysis
was carried out using SPSS 17.0 software. Logarithmic transfor-
mation was  applied to all reaction rates for data normalization.
Intra-assay differences within the anticoagulant concentration
range were compared using one-way analysis of variance (ANOVA),
with subsequent post-hoc analysis performed (Tukey’s test) if
significance was observed. A result of p < 0.05 was  considered sta-
tistically significant.
3. Results
3.1. Human plasma
In the first part of the study in plasma, optimization of the
fluorogenic anti-FXa assay was  undertaken by titrating FXa and
the SN-7 fluorogenic substrate within the ranges of 0.1–100 nM
and 8.3–33.3 M (Km = 125 M),  respectively. The best performing
assay was  selected in terms of lag time and reaction rate values, as
well as an optimal increase in fluorescence response. It was  found
that 100 nM FXa and 25 M fluorogenic substrate fulfilled all these
performance requirements. Subsequently, the fluorogenic anti-FXa
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Fig. 1. Log/lin dose–response curve of UFH within the range of 0–1.6 U/mL in human
pooled plasma. Inset: reaction progress curves of the ANSN-based fluorogenic anti-
FXa assay (100 nM FXa and 25 M ANSN fluorogenic substrate) using human pooled
plasma spiked with UFH (0–1.6 U/mL) (n = 3).
assay developed was analysed in human pooled plasma spiked with
UFH from 0 to 1.6 U/mL UFH every 0.2 U/mL. The reaction progress
curves shown in the inset of Fig. 1 showed decreasing reaction rates
and increasing lag times with increasing UFH concentration. This
indicates that the amount of FXa left over after the inhibition of
FXa by the complex formation of antithrombin-UFH, hence the flu-
orphore release, is inversely proportional to the concentration of
UFH present in the reaction mixture.
Reaction rates were calculated and data normalization was per-
formed by applying the log10-transformation to slope values (Fig. 1
and Table 1). Intra-assay variability was determined by means of
statistical analysis of the log mean slope values obtained at all UFH
concentrations. Statistical analysis of the data showed sensitivity of
the assay up to 1.6 U/mL UFH (p < 0.05) except that 0.6 and 1 U/mL,
and 1.2 and 1.4 U/mL, there were not significantly different from
one another. Table 1 outlines the mean of the log of the slopes, their
corresponding standard deviation (SD) and %CV values. As can be
seen, all CVs <2.5% indicating good reproducibility of results.
Table 1
Summary of averaged log10-transformation of reaction rates, SD and %CV values of
the fluorogenic anti-FXa assay within the low UFH range of 0–0.8 U/mL, high UFH
range of 0.6–1.6 U/mL in plasma (n = 3), and whole blood (n = 6).
[UFH] (U/mL) Plasma Whole blood
Low UFH range
log(dF/dt) SD CV (%) log(dF/dt) SD CV (%)
0 1.86 0.00 0.20 1.70 0.07 4.00
0.2  1.47 0.02 1.04 1.32 0.09 6.72
0.4  1.18 0.02 2.04 0.95 0.19 20.04
0.6  1.04 0.02 1.87 0.89 0.21 23.32
0.8  0.98 0.02 1.93 0.90 0.14 15.41
[UFH] (U/mL) Plasma
High UFH range
log(dF/dt) SD CV (%)
0.6 1.64 0.01 0.77
0.8  1.55 0.02 1.00
1  1.47 0.02 1.21
1.2  1.38 0.02 1.58
1.4  1.38 0.01 0.62
1.6  1.37 0.01 0.65
Fig. 2. Log/lin dose–response curve of UFH within the range of 0.6–1.6 U/mL in
human pooled plasma. Inset: reaction progress curve of the ANSN-based fluorogenic
anti-FXa assay (200 nM FXa and 75 M ANSN fluorogenic substrate) using human
pooled plasma spiked with UFH (0.6–1.6 U/mL) (n = 3).
Linear regression analysis was used to assess the behaviour
of the log of the slopes with increasing UFH concentration. Even
though the dynamic assay range was  previously indicated as
0–1.6 U/mL UFH, the entire range was not considered for the linear
calibration curve as the linear fit returned a poor regression coeffi-
cient. From the data, a linear regression was found within the assay
sensitive range of 0–0.6 U/mL (y = −1.37x + 1.80; R2 of 0.96).
In light of these results, it was considered appropriate to re-
optimize the fluorogenic anti-FXa assay to investigate if a high
range of UFH concentration could be monitored. Therefore, in the
second part of the study in plasma, 200 nM FXa was  titrated with
the SN-7 fluorogenic substrate over the range of 25–75 M.  The
requirements for the best performing assay were the same as pre-
viously indicated. Thus, 200 nM FXa and 75 M SN-7 fluorogenic
substrate were found to be the optimal assay concentrations. The
assay was tested within the UFH range of 0.6–1.6 U/mL. As can be
seen in the inset of Fig. 2, the reaction progress curve showed neg-
ligible lag time values, fluorescence intensity reached the upper
limit of the instrument and differences in slope values are shown
at different UFH concentrations.
Fig. 2 illustrates the log of the slopes at all UFH concentrations
studied. Statistical analysis demonstrated that UFH concentrations
at 0.2 U/mL intervals were statistically different from one another
(p < 0.001) from 0.6 to 1.2 U/mL. Table 1 summarises the log (dF/dt),
SD and %CV values. As can be seen, reproducibility was consistent
throughout the experiment with CVs <2%. Linear regression was
carried out within the statistically sensitive range and the linear
calibration curve equation was y = −0.43x + 1.90 with a correlation
coefficient of >0.99.
3.2. Whole blood
3.2.1. Absorption and emission spectra
The absorption and emission fluorescence spectra of blood sam-
ples from six donors were measured in this study to investigate
the effect of whole blood background fluorescence in the fluoro-
genic anti-FXa assay. Fig. 3 shows the absorption spectra of whole
blood from the six volunteers. As can be seen, the main absorption
peaks appear at ∼280, 345, 415, 541, and 576 nm,  with the maximal
absorption band at 415 nm.  Differences in absorbance intensities
can be observed between individuals, which can be attributed to
intrinsic donor characteristics.
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Fig. 3. Absorption spectra of whole blood from six donors evaluated from 280 to
1000 nm.
In order to investigate the whole blood autofluorescence, the
emission spectra were evaluated at the excitation wavelength of
352 nm,  which corresponds to that of the ANSN fluorophore (Fig. 4).
A unique, but broad peak was observed at ca. 470 nm with a fluo-
rescence intensity value of 500–600 arbitrary fluorescence units
(afu), which represents only 1% of the total fluorescence range of
the instrument (i.e. 0–60,000 afu). Thus the ANSN-based fluoro-
genic substrate proves to be a suitable label due to the almost
negligible background emission fluorescence of whole blood at the
wavelength excitation/emission pair of 352/470 nm.
3.2.2. Fluorogenic anti-FXa assay
Despite the very low emission fluorescence background shown
by whole blood when exciting at 352 nm,  the ANSN-based fluo-
rogenic anti-FXa assay had to be re-optimized due to the very low
increment in fluorescence signal. FXa and the SN-7 fluorogenic sub-
strate were titrated within the range of 300–500 nM and from 75 to
125 M,  respectively. Whole blood samples from six donors were
spiked with UFH concentrations within the range of 0–0.8 U/mL and
optimization was assessed as previously described for the plasma
assay. The best performing assay was found to be 350 nM FXa and
87.5 M SN-7 fluorogenic substrate, which was capable of sta-
tistically differentiating UFH from 0 to 0.4 U/mL every 0.2 U/mL.
Fig. 5 shows the normalized dose–response curve of UFH spiked
Fig. 4. Fluorescence emission spectra (400–850 nm)  of whole blood from six donors
at  excitation = 352 nm.
Fig. 5. Log/lin dose–response calibration curve of UFH within the range of
0–0.8 U/mL in whole blood samples (n = 6).
whole blood donor samples. As can be seen, as the concentration
of UFH increases, the log (dF/dt)  decreases. The calibration curve
plateaus beyond 0.4 U/mL UFH, rendering the assay insensitive
beyond 0.4 U/mL (Table 1). %CV values were <10% up to 0.2 U/mL
but increased to 15–25% between 0.4 and 0.8 U/mL. Linear regres-
sion analysis was  performed within the UFH statistically sensitive
range proving a linear calibration curve of y = −1.87x + 1.70 with an
R2 > 0.99.
4. Discussion
In the first part of this study, human pooled plasma sam-
ples were spiked with UFH concentrations from 0 to 1.6 U/mL
every 0.2 U/mL. Two optimized assays covering the low (from 0
to 0.6 U/mL) and high range (from 0.6 to 1.2 U/mL) for UFH were
developed. The fluorogenic anti-FXa assay concentrating on the
low range of UFH was  found to be 100 nM FXa and 25 M SN-7
fluorogenic substrate which was capable of statistically differen-
tiating the log of the slope values in commercial human pooled
plasma from 0 to 0.6 U/mL every 0.2 U/mL. A linear calibration
curve was  calculated returning a correlation coefficient of R2 = 0.96.
Good reproducibility of results was  achieved as indicated by CV
values below 2%. In relation to the UFH high range concentra-
tions, the optimized assay proved to be 200 nM FXa and 75 M
ANSN-based fluorogenic substrate. Assay sensitivity was statisti-
cally determined from 0.6 to 1.2 U/mL UFH with CV values less than
2%. The test revealed linearity within the statistically range with a
correlation coefficient of R2 > 0.99.
The low and high range fluorogenic anti-FXa assays developed
for UFH compare positively with the different commercially avail-
able chromogenic anti-FXa assays in terms of assay sensitivity and
reproducibility. Most of the tests from Chromogenix, American
Diagnostica Inc., Hyphen Biomed and Instrumentation Laboratory
to name just a few, measure therapeutic levels of UFH up to 1 U/mL
with CV values between 5 and 10%. One of the limitations of the
chromogenic anti-FXa assays is the lack of standardization as inves-
tigated by Ignjatovic et al. [25] and Kitchen et al. [26].
Another area of similar research is the development of flu-
orogenic thrombin generation assays in plasma [27] and whole
blood [21,28].  There are currently two  commercially available tests
from Thrombinoscope and Technoclone, which use plasma, but
lack of standardization is an issue [29–31].  Furthermore, it has
been reported by Hemker et al. [22] that the relationship between
thrombin generation and fluorescent activity is non-linear due to
substrate consumption and the inner filter effect. In the low and
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high UFH range fluorogenic anti-FXa assays developed in the study
presented here, linear calibration curves were calculated returning
correlation coefficients of 0.96 and >0.99, respectively.
In the second part of the study, whole blood experiments were
performed. Firstly, whole blood background fluorescence of the
six donor samples was examined using the absorption and emis-
sion spectra. The main absorption peaks appeared at ∼280, 345,
415, 541, and 576 nm in all samples, with the maximal absorp-
tion band at 415 nm.  These results agree well with the absorption
bands reported by Chen et al. [32] and Li et al. [33]. According to
Chen et al. [32], these absorption bands are similar to that of red
blood cells with the exception of the absorption peak at 280 nm.
The band at ∼280 nm corresponds to tryptophan with emission at
340 nm [33]. The bands at ∼345 nm,  415 nm,  and 576 nm have been
correlated with the absorption of iron porphyrin, which is part of
haemoglobin [34]. And the last two absorption peaks at ∼541 nm
and ∼576 nm correspond to oxyhemoglobin [35]. Emission spec-
tra of the six volunteers at 352 nm excitation wavelength, showed
a very low fluorescence intensity emission peak at ca. 470 nm.
Therefore, this emission band indicates the presence of an endoge-
nous fluorophore in whole blood with similar excitation-emission
wavelength pair to that of the ANSN fluorophore. The wave-
length pair at ca. 340–460 nm has been attributed to endogenous
reduced nicotinamide adenine dinucleotide or reduced nicoti-
namide adenine dinucleotide phosphate [33,36].  Nevertheless,
this fact does not represent an issue as the background fluores-
cence signal is only 1% of the total fluorescence range of the
instrument.
Secondly, the fluorogenic assay was re-optimized in whole
blood because of the small increment in fluorescence signal
obtained compared with the results in plasma. Considering that
whole blood contains several components, the fluorescence signal
could be diminished by light scattering effects as suggested Kim
et al. [35]. Thus the optimized fluorogenic anti-FXa assay in whole
blood was found to be 350 nM FXa and 87.5 M SN-7 fluorogenic
substrate, which was capable of statistically differentiating UFH
from 0 to 0.4 U/mL every 0.2 U/mL. Linear regression of the statis-
tically different data revealed good linearity (y = −1.87x + 1.70 and
an R2 > 0.99).
Several attempts have been made to develop sensitive and rapid
UFH whole blood assays for critical clinical applications (e.g. car-
diopulmonary bypass surgery, liver surgery, intensive care units)
but no success has been achieved to date. ACT whole blood point-
of-care devices are still widely used despite the drawbacks in
relation to precision and sensitivity to low UFH concentrations
[37,38]. It has been reported that the detection limit for heparin
in the ACT is ca. 0.5 U/mL therefore not being able to quan-
tify normal therapeutic UFH concentrations compared to anti-FXa
assays [39].
Murray et al. [30] compared the sensitivity of ACT, APTT, pro-
tamine titration, thromboelastography (TEG) and chromogenic
anti-FXa assays to heparin therapy, in vascular and cardiac sur-
gical patients. ACT was reported to be the least sensitive test to
identify residual heparin. In another study, the new thrombolytic
assessment system heparin management test (TAS HMT) was com-
pared with ACT and a chromogenic anti-FXa assay as the reference
method [37]. They documented that the new TAS HMT  did not
improve the performance of ACT. In addition, two fluorogenic
thrombin generation (TG) assays have been developed in whole
blood but not tested in the presence of UFH [21,28]. Tappenden
et al. [28] showed that the whole blood TG assay was more sensi-
tive than the PPP or PRP methods, but its imprecision was  higher
with CV values for peak height and endogenous thrombin poten-
tial of 14% and 13%, respectively. In our case, CVs were also higher
in whole blood than in plasma samples at all concentrations with
values between 4 and 20%.
And finally, considering that FXa is the method of reference for
measuring UFH, Hansen et al. [40] developed an ACT II anti-Xa assay
in whole blood with in vitro experiments revealing linearity up to
6 U/mL UFH. Despite its rapidity and ease-of-use, individual cali-
bration curves need to be carried out in the operating room, which
could hamper assay procedure.
5. Conclusions
Apart from two  recent publications on the development of fluo-
rogenic anti-FXa assays to monitor anticoagulant therapy in human
pooled plasma [23,24], to the best of our knowledge, no studies on
whole blood have been previously described. This paper outlines
the development of two  more fluorogenic anti-FXa assays using
one of the only two commercially available FXa fluorogenic sub-
strates. Two assays were developed to measure low (0–0.6 U/mL)
and high (0.6–1.2 U/mL) ranges of UFH in human pooled plasma.
Moreover, a linear calibration curve up to 0.4 U/mL UFH  using the
fluorogenic anti-FXa assay in whole blood was developed. Further
studies need to be undertaken to evaluate the potential of this latter
novel fluorogenic anti-FXa assay in critical clinical situations where
monitoring low UFH concentrations is needed.
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